Leishmaniasis is the second-most dreaded parasitic disease in the modern world, behind malaria. The lack of effective vaccines demand improved chemotherapy along with the development of lead compounds and newer targets. We report here that the pentacyclic triterpenoid, dihydrobetulinic acid (DHBA), is a novel lead compound for antileishmanial therapy. It acts by targeting DNA topoisomerases. DNA topoisomerase I and II activity was studied using relaxation and decatenation assays. Mechanistic studies were based on the decreased mobility of enzyme-bound DNA compared with free DNA and the differential mobility of nicked and supercoiled monomers in 1% agarose gel. Pulsed field gradient gel electrophoresis, confocal microscopy, and transmission electron microscopy were performed to assess cytotoxicity of the compound and ultrastructural damage of the parasite. Apoptosis was studied by the isolation of DNA from DHBA-treated parasites and subsequent electrophoresis in 1% agarose gel. DHBA inhibits growth of Leishmania donovani promastigotes and amastigotes with an IC 50 of 2.6 and 4.1 M respectively. The compound is a dual inhibitor of DNA topoisomerases that fails to induce DNA cleavage and acts by preventing the formation of enzyme-DNA binary complex, ultimately inducing apoptosis. Treatment of infected golden hamsters with the compound markedly reduces (> 92%) parasitic burden, both in spleen and liver. Interestingly, the 17-decarboxylated analogue, dihydrolupeol, does not inhibit DNA topoisomerase I and II, has no effect on parasitic growth, and also fails to induce apoptosis. DHBA is a potent antileishmanial agent that induces apoptosis by primarily targeting DNA topoisomerases. Therefore it is a strong candidate for use in designing new antileishmanial drugs.
INTRODUCTION
Kala-azar, or visceral leishmaniasis, is the most fatal form of leishmaniasis, affecting millions around the world. The toxicity of available drugs and the emergence of strains that are not responsive to drug therapy make the discovery of novel therapeutic agents imperative (1, 2) . In recent years, various new compounds with profound antileishmanial activity have been reported. Pilot study has demonstrated itraconazole to be a well-tolerated alternative treatment of mucocutaneous leishmaniasis (3) whereas the leaf extract of Kalanchoe pinnata was reported to reduce lesion size in cutaneous leishmaniasis (4) . Various compounds, such as atovaquone (5), WR6026 (6) , licochalcone A (7), ilmfosine (8) , and formycin B (9) have been reported to inhibit Leishmania donovani infection, the causative agent of visceral leishmaniasis. Unfortunately, all such compounds are effective only at higher doses and none of them have been recognized as oral drugs. Compounds like ketoconazole, fluconazole, and terbinafine were found to be less effective than antimonial agents in reducing hepatic parasitic load (10) . A plant-derived napthoquinone, lapachol, was reported to exert leishmanicidal activity in vitro with no in vivo therapeutic effect (11) . The only effective new oral compound to date is alkyl phospholipid miltefosine, which is effective against even antimony unresponsive cases (12) and presently is under phase III clinical trials (13) .
Search for antileishmanial agents have led scientists to newer therapeutic targets, which are essential for parasite growth and survival. DNA topoisomerases recently have emerged as principal therapeutic targets with a group of targeting agents having a broad spectrum of antiprotozoan activity (14) . They are ubiquitous enzymes, involved in many vital cellular processes (for example, replication, transcription, chromosomal segregation, genome stability, and so on [15] ) and are essential for cell survival. Studies by this laboratory have introduced potential antileishmanial agents that inhibit DNA topoisomerases (16) (17) (18) (19) . Camptothecin, an antitumor agent and a well-characterized topoisomerase I inhibitor, also is reported to have profound cytotoxic effect on Trypanosoma and Leishmania species (20) . Betulinic acid, a pentacyclic triterpenoid with a wide spectrum of pharmacological properties, is reported to be a potent inhibitor of DNA topoisomerases I and II (21) . Recently, we have reported that dihydrobetulinic acid (DHBA), a derivative of betulinic acid that exhibits anti-HIV activity (22, 23) , is another excellent inhibitor of DNA topoisomerase I (24) with the potential to become a lead therapeutic compound.
In the present study, we describe the antileishmanial activity of dihydrobetulinic acid (DHBA) ( Figure 1A ) on both L. donovani promastigotes and amastigotes. Dissecting the molecular mechanism, we show that similar to the parent compound (21) , DHBA inhibits DNA topoisomerases I and II by preventing enzyme-DNA binary complex formation. The compound causes extensive DNA damage with the ultimate induction of apoptosis. Oral and intramuscular administrations of DHBA to hamsters with established infection markedly reduce (> 92%) the splenic and hepatic parasitic burden. Correlating DHBA-mediated cell death and topoisomerase inhibition with that of dihydrolupeol, the decarboxylated analogue of DHBA, we propose that DHBA could be a novel lead compound for antileishmanial therapy.
MATERIALS AND METHODS

Isolation and Purification of DHBA
Betulinic acid, isolated from the leaves of Bacopa monniera as described (25) , was subjected to hydrogenation (26) to create DHBA (see Figure 1A ). DHBA was purified by chromatography over silica gel (60 to 120 mesh) and characterized by detailed spectral analysis of infrared, 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and mass spectroscopy. The final drug concentration was kept at 4% and 0.5% for all in vitro and cellular experiments, respectively.
Enzymes, DNA, and Chemicals
Kinetoplast DNA (kDNA) and DNA topoisomerase I and II were purified from Leishmania donovani strain UR6 promastigotes as described previously (27) (28) (29) . Plasmids pHOT1 and pRYG were purchased from Topogen, Inc. (Columbus, OH, USA) and pGEM4Z was purchased from Promega (Madison, WI, USA). All other chemicals were purchased from Sigma Chemical (St. Louis, MO, USA).
Parasite Culture and Growth Conditions
Leishmania strain UR6 and AG83 promastigotes were grown at 22°C in Rays modified media (30) and M 199 liquid media supplemented with 10% fetal calf serum.
DNA Topoisomerase I Assay
After treatment with topoisomerase I as described (18) , the type I DNA topoisomerase was assayed by decreased mobility of relaxed isomers of supercoiled pGEM4Z DNA in an agarose gel. The standard topoisomerase assay mixture (25 L) contained: 50 mM Tris HCl, pH 7.5, 5% glycerol, 50 mM KCl, 0.5 mM dithiothreitol (DTT), 10 mM MgCl 2 , 30 g/mL bovine serum albumin, 0.5 g pGEM4Z DNA, and 2 units of enzyme (1 unit is defined as the amount of enzyme required to convert 50% of 0.5 g supercoiled DNA substrate to the relaxed form under standard assay conditions). Reactions were carried out at 37 °C for 30 min and then stopped by adding 1% sodium dodecyl sulfate, 10 mM EDTA, 0.25 mg/mL bromophenol blue, and 15% glycerol. Samples were electrophoresed in 1% agarose gel in Tris-acetate-EDTA buffer (40 mM Tris-acetate, 2mM EDTA, pH 8) at 1.5 V/cm for 14 to 16 h at room temperature. Gels were stained with ethidium bromide (0.5 g/mL), destained with water, and photographed under UV illumination.
DNA Topoisomerase II Assay
The type II DNA topoisomerase was assayed by the decatenation of kDNA as described (19) . The standard decatenation assay mixture (25 L), containing 25 mM Tris HCl pH 7.9, 10 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, 50 mM NaCl, 10% glycerol, and 1 g kDNA, was incubated with 2 units of Leishmania topoisomerase II at 30 °C for 30 min. One unit is defined as the amount of enzyme required to release 50% of free minicircle DNA from 0.5 g substrate kDNA. Decatenations were monitored in 1% agarose gel as described above.
Gel Retardation Assay
pHOT1 and pRYG DNA, containing high affinity topoisomerase I binding and topoisomerase II cleavage site respectively (31, 32) , were used as substrate DNA. Experiments were conducted as described (24) . Substrate DNA was incubated with DNA topoisomerase I or II at 8°C for 15 min, in the presence or absence of DHBA, in 50 L binding buffer (24) . After incubation, the reaction mixtures were electrophoresed in 1% agarose gel containing 0.5 g/mL ethidium bromide at 4 °C as described above.
Analysis of DNA Cleavage
pHOT1 DNA and pRYG DNA were used as substrates for topoisomerase I and II mediated DNA cleavage, respectively. The standard reaction mixtures (50 L) contained 50 mM Tris HCl, pH 7.5, 2mM MgCl 2 , 0.2 mM DTT, 0.5 mM EDTA, 30 g/mL bovine serum albumin, and 20 g/mL pHOT1 DNA (for topoisomerase I) or 20 g/mL pRYG DNA (for topoisomerase II). Topoisomerase II assay mixtures also contained 2 mM ATP. Reactions were carried out with 50 units of enzymes at 37 °C for 30 min in presence and absence of drugs. The reactions were terminated by adding 1% sodium dodecyl sulfate, 150 g/mL proteinase K and incubated for 1 h at 37°C. DNA samples were electrophoresed in 1% agarose gel containing 0.5 g/mL ethidium bromide as described above.
Drug Treatment of Intact Leishmania Parasites and Isolation of DNA
Exponentially growing AG83 promastigotes (2.5 ϫ 10 6 cells/mL) were incubated at 22 °C for 15 min prior to the addition of DHBA and etoposide. Cells were further incubated at 22 °C for 30 min, washed, and lysed. DNA was extracted from the lysate, electrophoresed in 2% agarose gel, transferred into Hybond N membrane, and hybridized with 32 P-labeled kDNA (19) .
Cytotoxicity Assay
Cytotoxicity of the drugs was estimated by microscopic counting of the viable parasites by trypan blue exclusion method after treatment of L. donovani promastigotes with DHBA. Antileishmanial activity of DHBA on intracellular L. donovani amastigotes was carried out with thioglycollate-elicited peritoneal exudate as described (19) . At least 400 macrophages were examined for each cover slip. Antileishmanial activity was determined by calculating the number of amastigotes per 100 macrophages.
Study of Dyskinetoplastidy by Confocal Microscopy
Smears of drug-treated L. donovani AG83 promastigotes (2.5 ϫ 10 6 cells/mL) were assessed for dyskinetoplastic cells by ethidium bromide staining (0.1 g/mL in 1ϫ phosphate buffered saline containing 10% glycerol) under TCS-SP Leica confocal microscope system equipped with a krypton-argon mixed laser.
Study of Parasite Ultrastructure by TEM
For thin-section electron microscopy, cells were fixed with 6% glutaraldehyde in 0.125 M phosphate buffer (pH 7.2) for 14 to 16 h and then with 1% osmium tetroxide for 16 to 20 h at room temperature. The fixed cells were washed for 2 h in 0.5% uranyl acetate, dehydrated with increasing concentrations of ethanol, and embedded in Spurr medium at 70 °C for 48 h.
Sections were cut with a DuPont diamond knife in an LKB ultramicrotome, stained with uranyl acetate and lead citrate, and examined under JEOL 100 CX transmission electron microscope (33). 
Pulsed Field Gradient Gel Electrophoresis of DHBA-Treated Promastigotes
Different concentrations of DHBA were added to AG83 promastigotes (2.5 ϫ 10 6 cells/mL) and incubated at 22 °C up to 48 h. Cells were pelleted, lysed, and blocks prepared from low-melting agarose were subsequently digested with proteinase K (2 mg/mL) for 48 h at 55 °C as described (34) . Electrophoresis was carried out for 24 h with an initial and final switch time of 60 and 120 s respectively (current, 6 V/cm; including angle, 120°) in 0.5X Tris-borate-EDTA buffer.
Analysis of Apoptosis by Agarose Gel Electrophoresis
DNA, from exponentially growing AG83 cells (2.5 ϫ 10 6 cells/mL) treated with or without drugs, was isolated according to the protocol of Ward and others (35) and then electrophoresed on 1% agarose gel followed by ethidium bromide staining.
Determination of Antileishmanial Activity of the Compounds In Vivo
Male golden hamsters (6 wk, 60 to 75 g) with 2-wk-old established infection were administered 10 mg/kg body weight of DHBA both orally and by intramuscular injection for 6 wk before they were sacrificed. Control group received phosphate buffered saline (PBS). Splenic and liver parasitic loads were determined from impression smears after Giemsa staining and also from limiting dilution analysis of tissue homogenates. Results are expressed as the number of amastigotes/100 nuclei and the total parasitic load per organ, using the formula (36):
organ weight in mg ϫ the number of amastigotes per cell nucleus ϫ (2 ϫ 10 5 )
RESULTS
DHBA Inhibits DNA Topoisomerases I and II of L. donovani
DNA relaxation and kDNA decatenation assays were performed with 2 units of topoisomerases I and II with different concentrations of DHBA. Topoisomerase I activity was partially inhibited by 1 M DHBA and completely at 2 M (see Figure  1B ). This inhibition was comparable to the effect of a potent antitumor agent, camptothecin (37) (see Figure 1C) . During the decatenation assay, the topoisomerase II catalytic activity was completely inhibited by 5 M DHBA. This inhibition was comparable to the effect of a well-studied topoisomerase II inhibitor, etoposide (38) (see Figure 1D ). These results demonstrate that DHBA is a very potent dual inhibitor of L. donovani DNA topoisomerases. However, 50 M of the decarboxylated form of DHBA, dihydrolupeol (17-CH 3 instead of 17-CO 2 H) neither inhibited DNA topoisomerase I (see Figure 1E ) nor topoisomerase II (see Figure 1F ).
DHBA Inhibits Cleavable Complex Formation by Abrogating Topoisomerase-DNA Interaction
A topoisomerase reaction has 3 general mechanistic steps: 1) binding of the enzyme to the substrate DNA, 2) strand breakage and subsequent strand passage through the break leading to change in linking number, and 3) strand religation. Topoisomerase inhibition can be achieved by prevention of enzyme-DNA binary complex formation or by stabilization of enzyme-DNA putative reaction intermediate, that is, the cleavable complex. Gel retardation assays were performed to study the effect of DHBA on the initial topoisomerase-DNA binary complex formation. pHOT1 DNA, when incubated with 20 and 40 units of topoisomerase I at 8 ЊC for 30 min, showed retarded mobility indicating the formation of a protein-DNA complex that disappeared upon treatment with sodium dodecyl sulfate and proteinase K. When 40 units of topoisomerase I was preincubated with increasing concentrations of DHBA for 5 min, prior to the addition of pHOT1 DNA, no retardation was visible (Figure 2A ). When the same experiment was carried out with pRYG DNA and topoisomerase II, similar results were obtained with the complete disappearance of the retarded band upon increasing DHBA concentration (see Figure 2B) . These experiments clearly indicate that DHBA prevents the primary interaction between topoisomerases and substrate DNA.
Since the binary complex formation precedes the enzyme-DNA cleavable complex formation, it was expected that DHBA would not stabilize the cleavable complex. To confirm this, topoisomerase I-mediated DNA cleavage was assayed with different DHBA concentrations, keeping camptothecin as a positive control. Unlike camptothecin, which induced stabilization of the cleavable complex, DHBA had no effect (see Figure 2C) . Moreover, when topoisomerase I was preincubated with DHBA prior to the addition of camptothecin, the camptothecin-mediated cleavage was markedly reduced and completely inhibited at higher concentrations of DHBA (see Figure 2D) . Similar results were obtained with DHBA and topoisomerase II, where etoposide-mediated cleavage also was inhibited (see Figure 2E ). As both camptothecin and etoposide bind to the enzyme-DNA binary complex and no such complex formation is possible in presence of DHBA, this cleavage antagonism is expected.
To understand whether such in vitro observations were comparable in vivo, DHBA treated L. donovani AG83 promastigotes were assayed for drug-mediated linearization of kDNA minicircles. Unlike etoposide, which promoted DNA cleavage and resulted in a large increase in linear minicircle population, DHBA had no effect (see Figure 2F ). On the other hand, when promastigotes were incubated with DHBA for 30 min before the addition of etoposide, induction of minicircle linearization was inhibited as expected. It was interestng to note that when etoposide and DHBA together were added simultaneously, there was no appreciable change in linear minicircle population, indicating DHBA-enzyme interaction was dependent on time (see Figure 2G) . These experiments confirm that mode of inhibition is same, both in vitro and in vivo.
DHBA Inhibits Growth of L. donovani Promastigotes and Amastigotes
L. donovani AG83 promastigotes (2.5 ϫ 10 6 cells/mL) were incubated with 3 different concentrations of DHBA for 3 d. Next the numbers of live promastigotes were counted by trypan blue exclusion. On day 1, 65% percent growth was inhibited by 5 M DHBA, and 98% growth was inhibited on day 3, which was comparable to the inhibition achieved by 50 M DHBA on day 1. Figure 3B ). Therefore, DHBA is not only very effective against L. donovani promastigotes, but it also does not induce the generation of a resistant subpopulation. The IC 50 value, calculated to be 2.6 M (see Figure 3C ), varied inversely with incubation time (see inset, Figure 3C ). Peritoneal macrophages of BALB/c mice were infected with L. donovani AG83 promastigotes in vitro. Infected macrophages, after subsequent washing were incubated with 3 different concentrations of DHBA for 2 d. Similar to its effect on promastigotes, 5 M DHBA reduced the parasitic burden by 68%. Only 2% survival was observed upon incubation with 50 M DHBA (see Figure 3D) . IC 50 of inhibition was calculated to be 4.1 M. Dihydrolupeol, however, failed to decrease the parasitic burden. DHBA does not bind DNA, as evidenced by filter-binding assay, using labeled DNA and DHBA, and determination of melting temperature of DNA in presence and absence of DHBA (data not shown). Many DNA binding agents like acriflavine and berenil induce dyskinetoplastidy, a phenomenon where parasitic cells, though having mitochondrial membrane, completely lack kDNA (39) . Confocal microscopy of L. donovani AG83 promastigotes treated with 5 M DHBA for 24 h shows that DHBA is incapable of inducing dyskinetoplastidy. However, DHBA causes an extensive degranulation and defragmentation of total DNA. Some of the cells showed initial signs of nuclear compartmentalization and reduction of DNA intensity ( Figure 4A ). Bereniltreated parasites were mostly dyskinetoplastid (see Figure 4B ) whereas cells grown in media supplemented with 0.5% DMSO were completely healthy (see Figure 4C) .
In order to have a closer look at the effect of DHBA on L. donovani genomic DNA, transmission electron microscopy (TEM) was performed with both DHBA-treated and untreated promastigotes by embedding in spurr-blocks as described in Materials and Methods. Cells treated for 8 h with 5 M DHBA had intact plasma membrane ( Figure 5 ). However, the nuclei of such cells showed a particular chromatin margination, followed by its compaction toward the nuclear periphery, to form 1 or several frequent cupshaped masses, which are typical characteristics of apoptosis (40) . Examination of cells treated with 5 M DHBA for 16 h showed the disruption of outer cell membrane and blebbing formation. Upon examination of parasites incubated with 5 M DHBA for 24 h, total loss of cellular morphology and the generation of distinct compartments similar to apoptotic bodies were visible. Therefore, TEM data indicate that DNA degradation, as visualized by confocal microscopy, might actually be caused by programmed cell death. In order to substantiate these cellular observations in vitro, a pulsed field gradient gel electrophoresis was performed with DHBAtreated AG83 promastigotes. No genomic DNA was visible upon 48 h incubation with 5 M DHBA indicating complete fragmentation of DNA ( Figure 6 ).
DHBA Induces Apoptosis and Reduces Parasitic Burden
To further confirm that leishmanial cell death was due to an active process driven by the cell and not just the consequence of a passive degenerative process, cultured AG83 cells were treated with 50 M camptothecin; 5, 10, and 50 M DHBA; and 100 M dihydrolupeol for 24 h. Next their DNAs were isolated and electrophoresed on a 1% agarose gel (Figure 7 ). Parasites treated with camptothecin showed the formation of DNA ladders indicating apoptosis. Cells treated with DHBA showed similar band patterns with increase in intensity upon increasing DHBA concentration. However, even upon 24 h incubation, 100 M dihydrolupeol did not induce apoptosis.
The inhibition of catalytic activities of DNA topoisomerases, growth of parasites, and induction of apoptosis indicate that DHBA is a highly potent antileishmanial agent. The therapeutic potential of the compound was further substantiated by an in vivo experiment. Golden hamsters were infected with AG83 promastigotes and treated 2-wk after infection with DHBA (10 mg/kg body weight) for 6 wk. Compared with the infected, untreated hamsters, which showed a progressive and fatal visceral leishmaniasis, when DHBA was administered intramuscularly there was a drastic decrease in parasitic burden, 97% and 99% in spleen and liver respectively. Upon oral administration, splenic and liver parasitic burden decreased to 95.5% and 92.5% respectively ( Figure 8A ). 
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Giemsa-stained micrographs of spleen and liver smears for salinetreated, orally and intramuscularly DHBA-treated hamsters also show this profound effect and nearly complete reduction of parasitic burden (see Figure 8B ). More importantly, DHBA was found to be nontoxic as evident from the analysis of serum glutamate oxaloacetate transferase and serum glutamate pyruvate transferase of DHBA-treated animals. Also, the weight of infected, untreated hamsters reduced drastically compared with the weight of normal and DHBA-treated infected hamsters, indicating healthy recovery (data not shown).
DISCUSSION
We report here that DHBA is a dual inhibitor of both parasite DNA topoisomerases. It prevents interaction between the enzyme and substrate DNA, as evidenced from electrophoretic mobility shift assay. As a result, DHBA is unable to stabilize the cleavable complex and also antagonizes camptothecin or etoposide-mediated DNA cleavage. Therefore, the compound is very different from well-known topoisomerase inhibitors, such as, camptothecin (37) , etoposide (38) , amsacrine (38) , doxorubicin (41) , and so on, and is more similar to known class II inhibitors like merbarone (42) , aclarubicin (41) , chloroquine (43) , and so on. However, unlike all these compounds, DHBA does not interact with substrate DNA, and thus belongs to a rare group of dual inhibitors.
DHBA has a profound inhibitory effect on the growth of L. donovani promastigotes. IC 50 values of DHBA were calculated to be 4.1 M, 3.2 M, and 2.6 M when cells were incubated with the compound for a period of 24, 48, and 72 h. However, when incubated with dihydrolupeol, a 17-decarboxylated analogue of DHBA having no inhibitory effect on topoisomerases, there was no significant inhibition of promastigote growth. This suggests that inhibition of topoisomerases is a major step in the antileishmanial activity of DHBA. The possibility of emergence of a subpopulation of promastigotes resistant to DHBA was addressed by assessing the promastigote survival with 5 M DHBA on the residual viable population. It was observed that the residual population became highly susceptible to DHBA with repeated exposure to the compound. The IC 50 value of 4.1 M after 2-d treatment of amastigotes was comparable to the IC 50 value of 3.2 M upon inhibition of promastigotes growth after 2 d. However, it was not possible to calculate IC 50 of intracellular amastigotes for 1-and 3-d periods. Negligible infection was detected in control macrophages upon 1-d incubation with parasites, whereas 3-d incubation led to lysis of macrophages due to heavy infection.
With the establishment of DHBA as a potent antileishmanial agent that targets DNA topoisomerases, it was important to study the effect of the compound on the parasitic ultra structure. Though DHBA did not induce dyskinetoplastidy in L. donovani promastigotes, it caused chromatin margination in the nucleus and also dechromatinization of the genome as visualized under confocal microscope. TEM showed a strongly rearranged nucleus with progressive changes in cell shape along with surface bleb- 
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bing, which are characteristics of apoptosis (40) . That DHBA induces apoptosis of L. donovani promastigotes has been further confirmed by agarose gel electrophoresis. Dihydrolupeol not only loses its ability to inhibit DNA topoisomerases but also fails to induce apoptosis and ultimate cell death in L. donovani. This observation strongly supports a direct correlation between topoisomerase inhibition and apoptosis in L. donovani. The parent compound, betulinic acid, has been previously reported to induce apoptosis (44, 45) without any knowledge of a plausible target. Our study, for the first time, places DNA topoisomerase I and II on the shortlist as the primary cellular targets responsible for DHBA-induced apoptosis.
Various topoisomerase inhibitors have been reported to induce apoptosis, for example, doxorubicin (46) and salvicine (47) . Signal transduction pathways leading to cell-cycle arrest and apoptosis induced by DNA topoisomerase poisons also have been reported (48) . Our laboratory has identified a topoisomerase poison, luteolin, that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis in L. donovani (19) . Characteristic features of programmed cell death, such as nuclear condensation and nicking of DNA in the nucleus, already have been reported to exist in L. donovani (49) . We show here that the induction of programmed cell death in L. donovani promastigotes by DHBA is effectively translated into in vivo therapeutic effect. DHBA treatment of golden hamsters, both orally and intramuscularly, with established infection, almost completely reduced the parasitic burden in both spleen and liver. The degree of parasite reduction (10 3 times) was comparable to the effect of established drugs, such as amphotericin B with a degree of reduction of 10 3 to 10 5 times.
This profound antileishmanial effect of the compound, along with the absence of side effects, makes DHBA a highly promising candidate for antileishmanial therapy. Structure-function analysis of DHBA-topoisomerase interaction along with modeling studies can lead to the development of more potent drugs and also can facilitate the study of future drug resistance.
